Senaparib (IMP4297) is an orally bioavailable, highly selective PARP1/2 inhibitor demonstrating potent antitumor activity. It is a research tool for investigating DNA damage response pathways in cancers such as ovarian and breast, with studies showing efficacy in both cellular and animal models.